

[Home](#)[Validate](#)

General information about company		
Scrip code	532843	Enter the quarter ended date only
NSE Symbol	FORTIS	
MSEI Symbol	NOTLISTED	
ISIN	INE061F01013	
Name of the entity	FORTIS HEALTHCARE LIMITED	
Date of start of financial year	01-04-2024	
Date of end of financial year	31-03-2025	
Reporting Quarter Type	Yearly	
Date of Quarter Ending	31-03-2025	
Type of company	Equity	
Whether Annexure I (Part A) of the SEBI Circular dated December 31, 2024 related to Compliance Report on Corporate Governance is applicable to the entity?	Yes	
Whether Annexure I (Part B) of the SEBI Circular dated December 31, 2024 related to Investor Grievance Redressal Report is Applicable to the entity?	Yes	
Whether Annexure I (Part C) of the SEBI Circular dated December 31, 2024 related to Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies is Applicable to the entity?	Yes	
Whether Annexure I (Part D) of the SEBI Circular dated December 31, 2024 related to Disclosure of Imposition of Fine or Penalty is Applicable to the entity?	Yes	
Whether Annexure I (Part E) of the SEBI Circular dated December 31, 2024 related to Disclosure of Updates to Ongoing Tax Litigations or Disputes is Applicable to the entity?	Yes	
Whether Annexure I (Part F) of the SEBI Circular dated December 31, 2024 related to Disclosure Of Loans / Guarantees / Comfort Letters / Securities Etc. is Applicable to the entity?	Yes	
Risk management committee	Applicable	
Market Capitalisation as per immediate previous Financial Year	Top 500 listed entities	
Is SCORE ID Available ?	Yes	
SCORE Registration ID	f00057	
Reason For No SCORE ID		
Type of Submission	Original	
Remarks (website dissemination)	<input type="button" value="Add Notes"/>	
Remarks for Exchange (not for Website Dissemination)	<input type="button" value="Add Notes"/>	

[Prev](#)[Next](#)

Annexure I

Annexure I to be submitted by listed entity on quarterly basis
I. Composition of Board of Directors

Disclosure of notes on composition of board of directors explanatory

Add Notes

Whether the listed entity has a Regular Chairperson

Yes

Whether Chairperson is related to MD or CEO

No

Disqualification of Directors under section 164 of the Companies Act, 2013

Sr	Title (Mr / Ms)	Name of the Director	PAN	DIN	Category 1 of directors	Category 2 of directors	Category 3 of directors	Date of Birth	Whether the director is disqualified?	Start Date of disqualification	End Date of disqualification	Details of disqualification	Current status	Whether special resolution passed? [Refer Reg. 17(1A) of Listing Regulations]	Date of passing special resolution	Initial Date of appointment	Date of Re-appointment	Date of cessation	Tenure of director (in months)	No of Directorship in listed entities including this listed entity (Refer Regulation 17A of Listing Regulations)	No of Independent Directorship in listed entities including this listed entity (with reference to provision in regulation 17A(1) & reg. 17A(2))	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)	Reason for Cessation	Notes for not providing PAN	Notes for not providing DIN
1	Mr	Leo Puri	AALP0852A	01764813	Non-Executive - Independent Director	Chairperson		03-01-1961	No				Active	NA		27-12-2024			4.00	3	3	2	1			
2	Mr	Indrajit Banerjee	ADVP88026B	01365405	Non-Executive - Independent Director	Not Applicable		14-01-1956	No				Active	NA		27-04-2018	27-04-2023		83.00	2	2	4	2			
3	Mr	Ashutosh Raghuvanshi	ACBPAD998E	02775637	Executive Director	Not Applicable	CEO-MD	11-08-1962	No				Active	NA		19-03-2019	19-03-2025			1	0	2	0			
4	Ms	Suvilami Chakraborty	AADPC2775K	00106054	Non-Executive - Independent Director	Not Applicable		22-07-1966	No				Active	NA		27-04-2018	27-04-2023		83.00	2	2	3	1			
5	Mr	Dilip Kadambi	AEGPK8884A	02148022	Non-Executive - Independent Director	Not Applicable		02-08-1974	No				Active	NA		04-06-2020	01-08-2022			1	0	0	0			
6	Ms	Shalija Chandra	AACP1826A	03320688	Non-Executive - Independent Director	Not Applicable		17-06-1944	No				Active	Yes	28-06-2020	28-06-2020	28-06-2020		57.00	2	2	4	2			
7	Mr	Mehmet Ali Aydinlar	ZZZZ2999Z	10073483	Non-Executive - Non Independent Director	Not Applicable		24-07-1956	No				Active	NA		28-03-2023				1	0	0	0		5	
8	Mr	Tomo Nagahiro	ZZZZ2999Z	10074111	Non-Executive - Non Independent Director	Not Applicable		17-12-1975	No				Active	NA		28-03-2023				1	0	0	0		6	
9	Mr	Lim Tin Lin	ZZZZ2999Z	10118906	Non-Executive - Non Independent Director	Not Applicable		23-07-1978	No				Active	NA		04-05-2023				1	0	0	0		7	
10	Mr	Ashok Pandit	AALP92294C	09279899	Non-Executive - Non Independent Director	Not Applicable		24-12-1965	No				Active	NA		13-09-2023				1	0	2	0			
11	Mr	Pran Kumar Nair	ZZZZ2999Z	10348774	Non-Executive - Non Independent Director	Not Applicable		25-08-1960	No				Active	NA		11/09/2023				1	0	0	0		8	

Annexure 1

II. Composition of Committees

For this quarter kindly note the following points:
 1. Date of Appointment and Date of Cessation (if applicable) must be mandatorily filled for every Committee.
 2. Date of Appointment can be any day upto September 30, 2022.
 3. Date of Cessation must be for the current quarter only, i.e. July 1,2022 to September 30,2022

Disclosure of notes on composition of committees explanatory

Add Notes

Note: Please enter DIN. After entering DIN, Name of Committee members and Category 1 of Directors shall be prefilled automatically

Audit Committee Details							
Whether the Audit Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	01365405	Indrajit Banerjee	Non-Executive - Independent Director	Chairperson	13-11-2018		
2	00106054	Suvalaxmi Chakraborty	Non-Executive - Independent Director	Member	13-11-2018		
3	03320688	Shailaja Chandra	Non-Executive - Independent Director	Member	14-08-2020		
4	09279899	Ashok Pandit	Non-Executive - Non Independent Director	Member	30-10-2023		
5							
6							
7							
8							
9							
10							

Note: Please enter DIN. After entering DIN, Name of Committee members and Category 1 of Directors shall be prefilled automatically

Nomination and remuneration committee							
Whether the Nomination and remuneration committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	01365405	Indrajit Banerjee	Non-Executive - Independent Director	Member	13-11-2018		
2	03320688	Shailaja Chandra	Non-Executive - Independent Director	Chairperson	22-07-2021		
3	10348774	Prem Kumar Nair	Non-Executive - Non Independent Director	Member	10-11-2023		
4							
5							
6							
7							
8							
9							
10							

Note: Please enter DIN. After entering DIN, Name of Committee members and Category 1 of Directors shall be prefilled automatically

Stakeholders Relationship Committee							
Whether the Stakeholders Relationship Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	01365405	Indrajit Banerjee	Non-Executive - Independent Director	Member	13-11-2018		
2	03320688	Shailaja Chandra	Non-Executive - Independent Director	Chairperson	14-08-2020		
3	02775637	Ashutosh Raghuvanshi	Executive Director	Member	27-07-2021		
4							
5							
6							
7							
8							
9							
10							

Risk Management Committee							
Whether the Risk Management Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	02775637	Ashutosh Raghuvanshi	Executive Director	Member	15-10-2020		
2	03320688	Shailaja Chandra	Non-Executive - Independent Director	Chairperson	15-10-2020		
3	02407380	Anil Vinayak	Group Chief Operating Officer	Member	15-10-2020		9
4	03551067	Bishnu Prasad Panigrahi	Head Group Medical Strategy and Operations	Member	15-10-2020		10
5	02148022	Dilip Kadambi	Non-Executive - Non Independent Director	Member	29-09-2023		
6							
7							
8							
9							
10							

Note: Please enter DIN. After entering DIN, Name of Committee members and Category 1 of Directors shall be prefilled automatically

Corporate Social Responsibility Committee							
Whether the Corporate Social Responsibility Committee has a Regular Chairperson					No		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	03320688	Shailaja Chandra	Non-Executive - Independent Director	Member	01-10-2024		
2	01365405	Indrajit Banerjee	Non-Executive - Independent Director	Member	13-11-2018		
3	02775637	Ashutosh Raghuvanshi	Executive Director	Member	27-07-2021		
4							
5							
6							
7							
8							
9							
10							

Other Committee						
Sr	DIN Number	Name of Committee members	Name of other committee	Category 1 of directors	Category 2 of directors	Remarks
1						
2						
3						
4						
5						
6						
7						
8						
9						
10						

[Home](#)[Validate](#)

Annexure 1

III. Meeting of Board of Directors

Disclosure of notes on meeting of board of directors explanatory

[Add Notes](#)

Sr. No.	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Notes for not providing Date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors as on date of the meeting	Number of Directors present* (All directors including Independent Director)	No. of Independent Directors attending the meeting*
	Add Delete						
1	09-10-2024			Yes	10	10	3
2	08-11-2024	29		Yes	10	9	3
3	18-12-2024	39		Yes	10	8	3
4	27-12-2024	8		Yes	11	9	4
5	07-02-2025	41		Yes	11	9	4
6	20-03-2025	40		Yes	11	10	4

[Prev](#)[Next](#)

* to be filled in only for the current quarter meetings

Annexure 1

IV. Meeting of Committees

Disclosure of notes on meeting of committees explanatory							Add Notes			
Sr	Name of Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Name of other committee	Reason for not providing date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors in the Committee as on date of the meeting	Number of Directors Present (All Directors including Independent Director)	No. of Independent Directors attending the meeting*	No. of members attending the meeting (other than Board of Directors)
<div style="display: flex; justify-content: space-between;"> Add Delete </div>										
1	Audit Committee	25-10-2024				Yes	4	4	3	0
2	Audit Committee	07-11-2024	12			Yes	4	4	3	0
3	Audit Committee	06-02-2025	90			Yes	4	4	3	0
4	Audit Committee	12-03-2025	33			Yes	4	4	3	0
5	Nomination and remuneration committee	26-12-2024				Yes	3	3	2	0
6	Nomination and remuneration committee	07-02-2025	42			Yes	3	3	2	0
7	Stakeholders Relationship Committee	07-11-2024				Yes	3	3	2	0
8	Stakeholders Relationship Committee	06-02-2025	90			Yes	3	3	2	0
9	Corporate Social Responsibility Committee	25-10-2024				Yes	3	3	2	0
10	Risk Management Committee	12-03-2025	137			Yes	3	2	1	2

Prev

Next

* to be filled in only for the current quarter meetings

[Home](#)[Validate](#)**Annexure 1****V. Affirmations**

Sr	Subject	Compliance status (Yes/No)
1	The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015	Yes
2	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015 a. Audit Committee	Yes
3	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. b. Nomination & remuneration committee	Yes
4	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. c. Stakeholders relationship committee	Yes
5	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. d. Risk management committee (applicable to the top 1000 listed entities)	Yes
6	The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
7	The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
8	This report and/or the report submitted in the previous quarter has been placed before Board of Directors.	Yes
9	Any comments/observations/advice of Board of Directors may be mentioned here:	Add Notes

[Prev](#)[Next](#)**Annexure 1**

Sr	Subject	Compliance status
1	Name of signatory	Mr. Satyendra Chauhan
2	Designation	Company Secretary and Compliance Officer

Home

Validate

Details of Cyber security incidence		
Whether as per Regulation 27(2)(ba) of SEBI (LODR) Regulations, 2015 there has been cyber security incidents or breaches or loss of data or documents during the quarter	No	
Other details of cyber security incidence or breaches or loss of data event	Add Notes	
Number of cyber security incidence or breaches or loss of data event occurred during the quarter		
Sr.	Date of the event	Brief details of the event

Annexure II

Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)

I. Disclosure on website in terms of LODR Regulation

Sr	Item	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.	Web address
As per regulation 46(2) of the LODR:				
1.1	Details of business	Yes		https://www.fortishealthcare.com/about-us
1.2	Memorandum of Association and Articles of Association	Yes		https://www.fortishealthcare.com/investor/memorandum%20and%20articles%20of%20association/fhl%20-%20memorandum%20and%20articles%20of%20association
1.3	Brief profile of board of directors including directorship and full-time positions in body corporates	Yes		https://www.fortishealthcare.com/investors
2	Terms and conditions of appointment of independent directors	Yes		https://www.fortishealthcare.com/drupal-data/investors/Terms%2Band%2BConsitions%2Bof%2Bappointment%2Bof%2BIndependent%2BDirector.pdf
3	Composition of various committees of board of directors	Yes		https://www.fortishealthcare.com/investors/composition-of-committees/485
4	Code of conduct of board of directors and senior management personnel	Yes		https://www.fortishealthcare.com/drupal-data/investors/Code-of-Conduct.pdf
5	Details of establishment of vigil mechanism/ Whistle Blower policy	Yes		https://www.fortishealthcare.com/drupal-data/2023-12/Whistle%20Blower%20Policy.pdf
6	Criteria of making payments to non-executive directors	Yes		https://www.fortishealthcare.com/drupal-data/investors/0.16279600_1487930457_Policy-for-Compensation-and-Benefits.pdf
7	Policy on dealing with related party transactions	Yes		https://www.fortishealthcare.com/drupal-data/investors/Policy%2Bon%2BRelated%2BParty%2BTransactions.pdf
8	Policy for determining 'material' subsidiaries	Yes		https://www.fortishealthcare.com/drupal-data/investors/Policy%2Bon%2BMaterial%2BSubsidiary.pdf
9	Details of familiarization programmes imparted to independent directors	Yes		https://www.fortishealthcare.com/investors/familiarization-programmes/557
10	Email address for grievance redressal and other relevant details	Yes		https://www.fortishealthcare.com/drupal-data/2023-04/Grievance%20Redressal.pdf
11	Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances	Yes		https://www.fortishealthcare.com/drupal-data/2023-04/Grievance%20Redressal.pdf
12	Financial results	Yes		https://www.fortishealthcare.com/investors/audited-financial-results/473
13	Shareholding pattern	Yes		https://www.fortishealthcare.com/investors/shareholding-pattern/498
14	Details of agreements entered into with the media companies and/or their associates	NA		
15.1	(I) Schedule of analyst or institutional investor meet	Yes		https://www.fortishealthcare.com/investors/conference-call-invite/496
15.2	(II) Presentations prepared by the listed entity for analysts or institutional investors meet, post earnings or quarterly calls prior to beginning of such events.	Yes		https://www.fortishealthcare.com/investors/investor-presentations-&-transcripts/494
16	Audio recordings, video recordings, if any, and transcripts of post earnings or quarterly calls, by whatever name called, conducted physically or through digital means	Yes		https://www.fortishealthcare.com/investors/investor-presentations-&-transcripts/494
17	New name and the old name of the listed entity	NA		
18	Advertisements as per regulation 47 (1)	Yes		https://www.fortishealthcare.com/investors/newspaper-publications/521
19	Credit rating or revision in credit rating obtained	Yes		https://www.fortishealthcare.com/investors/credit-ratings/519
20	Separate audited financial statements of each subsidiary of the listed entity in respect of a relevant financial year	Yes		https://www.fortishealthcare.com/investors/financials-of-subsidiaries/478
21	Secretarial Compliance Report	Yes		https://www.fortishealthcare.com/investors/annual-secretarial-compliance-report/482
22	Materiality Policy as per Regulation 30 (4)	Yes		https://www.fortishealthcare.com/drupal-data/2024-02/Policy%20on%20Materiality%20of%20Events.pdf
23	Disclosure of contact details of KMP who are authorized for the purpose of determining materiality as required under regulation 30(5)	Yes		https://www.fortishealthcare.com/drupal-data/2024-02/Policy%20on%20Materiality%20of%20Events.pdf
24	Disclosures under regulation 30(8)	Yes		https://www.fortishealthcare.com/investors/disclosure-under-reg.-30-of-sebi-(lodr)/513
25	Statements of deviation(s) or variations(s) as specified in regulation 32	NA		
26	Dividend Distribution policy as per Regulation 43A(1)	Yes		https://www.fortishealthcare.com/drupal-data/investors/Policy%2Bon%2BDividend%2BDistribution.pdf
26.1	Annual return as provided under section 92 of the Companies Act, 2013	Yes		https://www.fortishealthcare.com/investors/annual-return/479
26.2	Employee Benefit scheme documents framed in terms of SEBI (SBEB) Regulations, 2021	NA		
27	Confirmation that the above disclosures are in a separate section as specified in regulation 46(2)	Yes		https://www.fortishealthcare.com/investors
28	Compliance with regulation 46(3) with respect to accuracy of disclosures on the website and timely updating	Yes		https://www.fortishealthcare.com/investors
29	Disclosure of notes on website in terms of Listing Regulations explanatory [Text Block]		Add Notes	

Home

Validate

Annexure II

II. Annual Affirmations

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
1	Independent director(s) have been appointed in terms of specified criteria of 'independence' and/or 'eligibility'	16(1)(b)	Yes	
2	Board composition	17(1), 17(1A) & 17(1C), 17(1D) & 17(1E)	Yes	
3	Meeting of Board of directors	17(2)	Yes	
4	Quorum of Board meeting	17(2A)	Yes	
5	Review of Compliance Reports	17(3)	Yes	
6	Plans for orderly succession for appointments	17(4)	Yes	
7	Code of Conduct	17(5)	Yes	
8	Fees/compensation	17(6)	Yes	
9	Minimum Information	17(7)	Yes	
10	Compliance Certificate	17(8)	Yes	
11	Risk Assessment & Management	17(9)	Yes	
12	Performance Evaluation of Independent Directors	17(10)	Yes	
13	Recommendation of Board	17(11)	Yes	
14	Maximum number of Directorships	17A	Yes	
15	Composition of Audit Committee	18(1)	Yes	
16	Meeting of Audit Committee	18(2)	Yes	
17	Role of Audit Committee and information to be reviewed by the audit committee	18(3)	Yes	
18	Composition of nomination & remuneration committee	19(1) & (2)	Yes	
19	Quorum of Nomination and Remuneration Committee meeting	19(2A)	Yes	
20	Meeting of Nomination and Remuneration Committee	19(3A)	Yes	
21	Role of Nomination and Remuneration Committee	19(4)	Yes	
22	Composition of Stakeholder Relationship Committee	20(1), 20(2) & 20(2A)	Yes	
23	Meeting of Stakeholders Relationship Committee	20(3A)	Yes	
24	Role of Stakeholders Relationship Committee	20(4)	Yes	
25	Composition and role of risk management committee	21(1),(2),(3),(4)	Yes	
26	Meeting of Risk Management Committee	21(3A)	Yes	
27	Quorum of Risk Management Committee meeting	21(3B)	Yes	
28	Gap between the meetings of the Risk Management Committee	21(3C)	NA	
29	Vigil Mechanism	22	Yes	
30	Policy for related party Transaction	23(1), (1A), (5), (6), & (8)	Yes	
31	Prior or Omnibus approval of Audit Committee for all related party transactions	23(2), (3)	Yes	
32	Approval for material related party transactions	23(4)	Yes	
33	Disclosure of related party transactions on consolidated basis	23(9)	Yes	
34	Composition of Board of Directors of unlisted material Subsidiary	24(1)	Yes	
35	Other Corporate Governance requirements with respect to subsidiary of listed entity	24(2),(3),(4),(5) & (6)	Yes	
36	Alternate Director to Independent Director	25(1)	NA	
37	Maximum Tenure	25(2)	Yes	
38	Appointment, Re-appointment or removal of an Independent Director through special resolution or the alternate mechanism	25(2A)	Yes	
39	Meeting of independent directors	25(3) & (4)	Yes	
40	Familiarization of independent directors	25(7)	Yes	
41	Declaration from Independent Director	25(8) & (9)	Yes	
42	Directors and Officers insurance	25(10)	Yes	
43	Confirmation with respect to appointment of Independent Directors who resigned from the listed entity	25(11)	Yes	
44	Memberships in Committees	26(1)	Yes	
45	Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel	26(3)	Yes	
46	Policy with respect to Obligations of directors and senior management	26(2) & 26(5)	Yes	
47	Approval of the Board and shareholders for compensation or profit sharing in connection with dealings in the securities of the listed entity	26(6)	Yes	
48	Vacancies in respect Key Managerial Personnel	26A(1) & 26A(2), 26A(3)	Yes	
Any other information to be provided				Add Notes

Prev

Next

Annexure II

1	Name of signatory	Mr. Satyendra Chauhan
2	Designation	Company Secretary and Compliance Officer

[Home](#)[Validate](#)

Annexure II		
III. Affirmations		
Sr	Particulars	Compliance status (Yes/No/NA)
1	The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied	Yes
Any other information to be provided		Add Notes

[Prev](#)[Next](#)

Annexure II		
1	Name of signatory	Mr. Satyendra Chauhan
2	Designation	Company Secretary and Compliance Officer

[Home](#)[Validate](#)

Signatory Details

Name of signatory	Mr. Satyendra Chauhan
Designation of person	Company Secretary and Compliance Officer
Place	Gurugram
Date	30-04-2025

[Prev](#)

[Home](#)[Validate](#)

Investor Grievance Details

No. of investor complaints pending at the beginning of Quarter	0
No. of investor complaints received during the Quarter	0
No. of investor complaints disposed off during the Quarter	0
No. of investor complaints those remaining unresolved at the end of the Quarter	0

[Home](#)[Validate](#)**Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies-**

The details of acquisition of shares or voting rights in unlisted companies during the quarter in terms of sub-para 1 of para A of Part A of Schedule III are given below:

Any Other Information for Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies

[Add Notes](#)

Sr. No.	Name of the unlisted company in which shares or voting rights have been acquired	Date of acquisition	Aggregate holding (% shares or voting rights) as at the end of the previous quarter	% shares or voting rights acquired during the quarter	Aggregate holding (% shares or voting rights) as at the end of the quarter
1	Agilus Diagnostics Limited	17-01-2025	65.29%	23.91%	89.20%

[Add](#)[Delete](#)

[Home](#)[Validate](#)**Disclosure of Imposition of Fine or Penalty**

The details of imposition of fine or penalty during the quarter in terms of sub-para 20 of para A of Part A of Schedule III are given below:

Any Other Information for Disclosure of Imposition of Fine or Penalty

[Add Notes](#)

Sr. No.	Name of the authority	Nature and details of the action(s) taken or order(s) passed	Date of receipt of direction or order, including any ad interim or interim orders, or any other communication from the authority	Details of the violation(s)/ contravention(s) committed or alleged to be committed	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible
	Add	Delete			
1	Central Ground Water Authority	To obtain NOC from CGWA 1. Penalty of Rs.(1,00,000.00) on account of (Late submission).	02-01-2025	<p>The NOC from CGWA was one of critical NOC necessarily required for obtaining the Consent to Establish (CTE); Consent to Operate (CTO) & BMW Authorization from Rajasthan State Pollution Control Board (RSPCB). This vital requirement of NOC came up during our plan execution for raising the bed capacity which was denied/REJECTED due to the absences of this NOC & EC.</p> <p>This was applicable since inception of the hospital and we must have obtained this primarily as on the basis of this NOC, all other licenses are granted and renewed such as CTO, CTE & BMW Authorization and also Environment Clearance. However, we were not able to obtain this NOC</p>	Rs. 100000/-

Disclosure of Updates to Ongoing Tax Litigations or Disputes				
The updates on tax litigations or disputes in terms of sub-para 8 of para B of Part A of Schedule III read with corresponding provisions of Annexure 18 of the Master Circular are given below:				
Any Other Information for Disclosure of Updates to Ongoing Tax Litigations or Disputes				Add Notes
Sr. No.	Name of the opposing party	Date of initiation of the litigation / dispute	Status of the litigation / dispute as per last disclosure	Current status of the litigation / dispute
Add	Delete			
1	Income Tax Department	09-08-2021	On appeal by the Company (Fortis Hospitals Limited) for Assessment Year 2017-18, Case was referred to Transfer Pricing Officer (TPO) for Transfer Pricing (TP) Assessment. TPO has passed order on 29.01.2021 with no adverse inference. Later on, Assessing Officer (AO) has passed assessment order dt. 09.08.2021 making disallowances:- -Rs. 3,26,81,835 u/s 14A -Rs. 28,96,72,142 - unexplained cash credit u/s 68 computed as per section 115BBE @ 60%. Amount under litigation is Rs. 26,56,61,808 and the matter is currently pending before Commissioner of Income Tax (Appeals).	No change
2	Income Tax Department	29-09-2021	On appeal by the Company (Fortis Hospitals Limited) for Assessment Year 2019-20, Assessment was completed vide order dated 29.09.2021 making disallowances on account of:- -14A r/w Rule 8D at Rs. 37,26,805/- -Disallowance of bad debts at Rs. 25,49,02,000/- -Advances from customers/patients at Rs. 42,65,12,000/- -Disallowance of ICDs based on SEBI orders at Rs. 402,43,62,000/- Assessing income at Rs. 108,58,49,650/- as against loss at Rs. 367,36,53,160/- Amount under litigation is Rs. 44,04,72,119 and the matter is currently pending before Commissioner of Income Tax (Appeals).	No change
3	Income Tax Department	11-02-2019	On appeal by the Company (Fortis Hospital Limited) for Assessment Year 2015-16, Case was referred to Transfer Pricing Officer (TPO) for Transfer Pricing (TP) Assessment. TPO has passed order proposing adjustment. Later on, Assessing Officer (AO) has passed assessment order confirming the adjustment proposed in TP Order, being interest amount paid on Compulsorily Convertible Debentures (CCDs) issued by the company. Amount under litigation is Rs. 71,18,64,960 and the matter is currently pending before Commissioner of Income Tax (Appeals).	No change
4	Income Tax Department	03-06-2021	On appeal by the Company (Fortis Hospital Limited) for Assessment Year 2017-18, Case was referred to Transfer Pricing Officer (TPO) for Transfer Pricing (TP) Assessment. TPO has passed order proposing adjustment. Later on, Assessing Officer (AO) has passed assessment order confirming the adjustment proposed in TP Order, being interest amount paid on Compulsorily Convertible Debentures (CCDs) issued by the company. Amount under litigation is Rs. 56,11,28,717 and the matter is currently pending before Commissioner of Income Tax (Appeals).	No change
5	Income Tax Department	24-11-2021	On appeal by the Company (Fortis Hospital Limited) for Assessment Year 2018-19, Case was referred to Transfer Pricing Officer (TPO) for Transfer Pricing (TP) Assessment. TPO has passed order on 30.07.2021 proposing adjustment amounting to INR 74.63 Cr which is interest expense claimed on Compulsorily Convertible Debentures (CCDs) issued by the company to FGHIPL and consultancy expenses on the same. Later on, Assessing Officer (AO) has passed assessment order dt. 24.11.2021 confirming the adjustment proposed in TP Order. Amount under litigation is Rs. 33,26,19,748 and the matter is currently pending before Commissioner of Income Tax (Appeals).	No change
6	Income Tax Department	28-03-2005	In case of Escorts Heart Institute and Research Centre Limited, On appeal by the Department for Assessment Year 2001-02, Assessment was done u/s 143(1)(a) on 29.08.2002. The Assessing Officer reopened the assessment and passed the assessment order dated 28.03.2005 making an addition of Rs. 149.09 crores. The Assessing Officer held that registration of a society as a company under Part IV of the Companies Act tantamount to a transfer of assets and hence alleged addition on account of capital gain has been made. Company's appeal allowed by Income tax appellate tribunal, revenue has filed appeal before Delhi High Court. Amount under litigation is Rs. 1,05,32,00,000 and the matter is currently pending before Delhi High Court.	No change
7	Income Tax Department	15-02-2017	In case of International Hospital Limited for Assessment Year 2013-14, Case was referred to Transfer Pricing Officer (TPO) for Transfer Pricing (TP) Assessment. TPO has passed order on 31.10.2016 proposing adjustment amounting to INR 569 million which is interest expense claimed on Compulsorily Convertible Debentures (CCDs) issued by the company to FGHIPL. Later on, Assessing Officer (AO) has passed assessment order dt. 15.02.2017 confirming the adjustment proposed in TP Order and also making disallowance u/s 14A read with rule 8D amounting to INR 60 million and u/s 36(1)(va) amounting to INR 0.26 million. An appeal filed before the Commissioner of Income-tax (Appeals), New Delhi on 30.03.2017 has been decided. Further appeal filed before ITAT on 18.04.2019. Departmental also in appeal. Demand raised at Rs. 15,01,91,860/- vide order passed u/s 143(3), the same was revised at Rs. 34,18,72,340/- vide order dated 17.05.2018 passed u/s 154. Amount under litigation is Rs. 34,18,72,340/- and the matter is currently pending before Income Tax Appellate Tribunal.	No change
8	Income Tax Department	10-05-2021	In case of International Hospital Limited for Assessment Year 2017-18, Case was referred to Transfer Pricing Officer (TPO) for Transfer Pricing (TP) Assessment. TPO has passed order dated 11.01.2021 proposing adjustment of Rs. 92,83,08,762/-. Later on, Assessing Officer (AO) has passed assessment order u/s 143(3) dated 10.05.2021 confirming the adjustment proposed in TP Order and making further disallowance u/s 36(1)(iii) at Rs. 71,00,77,700/- and u/s 36(1)(va) at Rs. 9,05,271/- thereby raising a demand of Rs. 39.89Cr. Amount under litigation is Rs. 39,89,16,838/- and the matter is currently pending before Commissioner of Income Tax (Appeals).	No change
9	Income Tax Department	25-11-2021	In case of International Hospital Limited for Assessment Year 2018-19, Case was referred to Transfer Pricing Officer (TPO) for Transfer Pricing (TP) Assessment. TPO has passed order dated 30.07.2021 proposing adjustment of Rs. 228,08,64,295/- Later on, Assessing Officer (AO) has passed assessment order u/s 143(3) dated 25.11.2021 confirming the adjustment proposed in TP Order and making disallowance u/s 36(1)(iii) at Rs. 75,05,77,475/- and u/s 36(1)(va) at Rs. 12,00,00,000/- thereby raising a demand of Rs. 187.35Cr. Amount under litigation is Rs. 1,87,35,22,640 and the matter is currently pending before Commissioner of Income Tax (Appeals).	No change
10	Income Tax Department	21-03-2024	Fortis Hospitals Limited, a material subsidiary of the Company has received an Income tax assessment order for Assessment Year 2022-23 (Financial Year 2021-22), wherein a demand of Rs. 89.53 Crores (including interest of Rs. 9.54 Crores) has been raised. The matter is currently pending before Commissioner of Income Tax (Appeals).	No change
11	Office of the Principal Commissioner* GST, Gurugram,	18-07-2024	GST Department of Haryana has issued Show Cause Notice alleging that the company i.e. Fortis Hospitals Limited is charging MRP from IPO patient for medicine, consumable and implant which include GST and not remitting the same to government exchequer. Thus, the subsidiary Company i.e. Fortis Hospitals Limited has filed the writ petition by challenging the show cause notice issued by the Office of the Principal Commissioner GST, Gurugram. Amount under litigation is Rs. 61.19 Crore plus interest and penalty and the matter is currently pending before Punjab and Haryana High Court.	No change
12	DCIT	30-11-2018	Pending before CIT(A) / NFAC	Disposed off in favour of assessee by Order of CIT (A), dated 27.05.2024. However DCIT, Income Tax - Gurugram filed an appeal before ITAT. Now the matter is pending with ITAT.
13	DCIT	19-01-2018	Pending before CIT(A) / NFAC	Pending before CIT(A) / NFAC
14	DCIT	18-01-2019	Pending before CIT(A) / NFAC	Pending before CIT(A) / NFAC
15	ACIT	30-06-2020	Pending before CIT(A) / NFAC	2 crores more paid under protest on 11.03.2025. Total paid under protest is Now Rs. 6 crores.